U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Leiomyosarcoma

MedGen UID:
1714364
•Concept ID:
C5237455
•
Neoplastic Process

Definition

A leiomyosarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Leiomyosarcoma

Professional guidelines

PubMed

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litière S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Cancer 2020 Jun 1;126(11):2637-2647. Epub 2020 Mar 4 doi: 10.1002/cncr.32795. PMID: 32129883
Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Akin S, Dizdar O, Karakas Y, Turker A, Kars A
Curr Probl Cancer 2018 May-Jun;42(3):344-349. Epub 2018 Jan 31 doi: 10.1016/j.currproblcancer.2018.01.011. PMID: 29576383

Recent clinical studies

Etiology

Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma.
Madanat-Harjuoja LM, Klega K, Lu Y, Shulman DS, Thorner AR, Nag A, Tap WD, Reinke DK, Diller L, Ballman KV, George S, Crompton BD
Clin Cancer Res 2022 Jun 13;28(12):2579-2586. doi: 10.1158/1078-0432.CCR-21-3951. PMID: 35561344Free PMC Article
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litière S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Cancer 2020 Jun 1;126(11):2637-2647. Epub 2020 Mar 4 doi: 10.1002/cncr.32795. PMID: 32129883
Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Akin S, Dizdar O, Karakas Y, Turker A, Kars A
Curr Probl Cancer 2018 May-Jun;42(3):344-349. Epub 2018 Jan 31 doi: 10.1016/j.currproblcancer.2018.01.011. PMID: 29576383
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.
Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Muda AO, Gronchi A, Casali P, Dei Tos AP, Tonini G
Br J Cancer 2017 Jul 25;117(3):340-346. Epub 2017 Jun 22 doi: 10.1038/bjc.2017.187. PMID: 28641307Free PMC Article
Uterine sarcomas--recent progress and future challenges.
Seddon BM, Davda R
Eur J Radiol 2011 Apr;78(1):30-40. Epub 2011 Jan 17 doi: 10.1016/j.ejrad.2010.12.057. PMID: 21247711

Diagnosis

Initial Clinical Experience With Novel Directional Low-Dose Rate Brachytherapy for Retroperitoneal Sarcoma.
Vidri RJ, Howell KJ, Meyer JE, Rivard MJ, Emrich JG, Price RA, Farma JM, Turian JV, Poli J, Wang D
J Surg Res 2021 Dec;268:411-418. Epub 2021 Aug 17 doi: 10.1016/j.jss.2021.06.080. PMID: 34416413
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litière S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Cancer 2020 Jun 1;126(11):2637-2647. Epub 2020 Mar 4 doi: 10.1002/cncr.32795. PMID: 32129883
Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Akin S, Dizdar O, Karakas Y, Turker A, Kars A
Curr Probl Cancer 2018 May-Jun;42(3):344-349. Epub 2018 Jan 31 doi: 10.1016/j.currproblcancer.2018.01.011. PMID: 29576383
Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.
Galizia D, Palesandro E, Nuzzo AM, Pignochino Y, Aliberti S, Aglietta M, Grignani G
Oncol Res 2013;20(10):483-90. doi: 10.3727/096504013x13685487925130. PMID: 24308159
Uterine sarcomas--recent progress and future challenges.
Seddon BM, Davda R
Eur J Radiol 2011 Apr;78(1):30-40. Epub 2011 Jan 17 doi: 10.1016/j.ejrad.2010.12.057. PMID: 21247711

Therapy

Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients.
Turinetto M, Meeus P, Ray-Coquard I
Curr Opin Oncol 2023 Jul 1;35(4):288-291. Epub 2023 May 18 doi: 10.1097/CCO.0000000000000961. PMID: 37222199
A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma.
Chen TW, Hsu CL, Hong RL, Lee JC, Chang K, Yu CW, Chen SC, Guo JC, Chen ML, Hsu MC, Kung TF, Cheng AL, Yen CC
Clin Cancer Res 2022 Dec 1;28(23):5058-5065. doi: 10.1158/1078-0432.CCR-22-2092. PMID: 36129471
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma.
Wagner MJ, Zhang Y, Cranmer LD, Loggers ET, Black G, McDonnell S, Maxwell S, Johnson R, Moore R, Hermida de Viveiros P, Aicher L, Smythe KS, He Q, Jones RL, Pollack SM
Clin Cancer Res 2022 Jun 1;28(11):2306-2312. doi: 10.1158/1078-0432.CCR-22-0240. PMID: 35349638Free PMC Article
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litière S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Cancer 2020 Jun 1;126(11):2637-2647. Epub 2020 Mar 4 doi: 10.1002/cncr.32795. PMID: 32129883
Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Akin S, Dizdar O, Karakas Y, Turker A, Kars A
Curr Probl Cancer 2018 May-Jun;42(3):344-349. Epub 2018 Jan 31 doi: 10.1016/j.currproblcancer.2018.01.011. PMID: 29576383

Prognosis

Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Akin S, Dizdar O, Karakas Y, Turker A, Kars A
Curr Probl Cancer 2018 May-Jun;42(3):344-349. Epub 2018 Jan 31 doi: 10.1016/j.currproblcancer.2018.01.011. PMID: 29576383
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.
Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Muda AO, Gronchi A, Casali P, Dei Tos AP, Tonini G
Br J Cancer 2017 Jul 25;117(3):340-346. Epub 2017 Jun 22 doi: 10.1038/bjc.2017.187. PMID: 28641307Free PMC Article
Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.
Galizia D, Palesandro E, Nuzzo AM, Pignochino Y, Aliberti S, Aglietta M, Grignani G
Oncol Res 2013;20(10):483-90. doi: 10.3727/096504013x13685487925130. PMID: 24308159
Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway.
Italiano A, Kind M, Stoeckle E, Jones N, Coindre JM, Bui B
Anticancer Drugs 2011 Jun;22(5):463-7. doi: 10.1097/CAD.0b013e3283442074. PMID: 21301319
Uterine sarcomas--recent progress and future challenges.
Seddon BM, Davda R
Eur J Radiol 2011 Apr;78(1):30-40. Epub 2011 Jan 17 doi: 10.1016/j.ejrad.2010.12.057. PMID: 21247711

Clinical prediction guides

A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma.
Wagner MJ, Zhang Y, Cranmer LD, Loggers ET, Black G, McDonnell S, Maxwell S, Johnson R, Moore R, Hermida de Viveiros P, Aicher L, Smythe KS, He Q, Jones RL, Pollack SM
Clin Cancer Res 2022 Jun 1;28(11):2306-2312. doi: 10.1158/1078-0432.CCR-22-0240. PMID: 35349638Free PMC Article
Initial Clinical Experience With Novel Directional Low-Dose Rate Brachytherapy for Retroperitoneal Sarcoma.
Vidri RJ, Howell KJ, Meyer JE, Rivard MJ, Emrich JG, Price RA, Farma JM, Turian JV, Poli J, Wang D
J Surg Res 2021 Dec;268:411-418. Epub 2021 Aug 17 doi: 10.1016/j.jss.2021.06.080. PMID: 34416413
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litière S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Cancer 2020 Jun 1;126(11):2637-2647. Epub 2020 Mar 4 doi: 10.1002/cncr.32795. PMID: 32129883
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.
Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Muda AO, Gronchi A, Casali P, Dei Tos AP, Tonini G
Br J Cancer 2017 Jul 25;117(3):340-346. Epub 2017 Jun 22 doi: 10.1038/bjc.2017.187. PMID: 28641307Free PMC Article
Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway.
Italiano A, Kind M, Stoeckle E, Jones N, Coindre JM, Bui B
Anticancer Drugs 2011 Jun;22(5):463-7. doi: 10.1097/CAD.0b013e3283442074. PMID: 21301319

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...